Danaher Corporation announced that Executive Vice President and Chief Financial Officer, Matt McGrew will be presenting at the Barclays Global Healthcare Conference on Thursday, March 11, 2021 at 11:30 a.m. ET . The audio will be simultaneously webcast on . ABOUT DANAHER Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life ...

- Danaher Corporation (NYSE: DHR) announced that Executive Vice President and Chief Financial Officer, Matt McGrew will be presenting at the Barclays Global Healthcare Conference on Thursday, March 11, 2021 at 11:30 a.m. ET . The audio will be simultaneously webcast on www.danaher.com .

ABOUT DANAHER
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of approximately 69,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential . For more information, please visit www.danaher.com .

Cision View original content: http://www.prnewswire.com/news-releases/danaher-to-present-at-barclays-global-healthcare-conference-301240975.html

SOURCE Danaher Corporation

News Provided by PR Newswire via QuoteMedia

UPDATED - Leveljump Healthcare Corp. Announces 14.6% Minority Investment in Real Time Medical

UPDATED - Leveljump Healthcare Corp. Announces 14.6% Minority Investment in Real Time Medical

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce that, subject to regulatory approval, it has agreed to acquire an outstanding 14.6% minority equity interest in Real Time Medical Inc. ("RTM"), a private Ontario company, in exchange for 2,494,576 units (a "Unit") of Leveljump. Each Unit will be issued at a price of $0.66 per Unit with each Unit being comprised of three (3) Leveljump common shares at a deemed price of $0.22 per share and one (1) share purchase warrant of Leveljump, each warrant entitling the holder to acquire one additional common share of Leveljump at a price of $0.35 per common share on or before December 31, 2023.

The equity interest in RTM was acquired through a mini-tender offer to the shareholders of RTM dated November 1, 2021 whereby JUMP offered to acquire up to 19.9% of RTM in exchange for the Units. The holders of the RTM shares who have tendered are all accredited investors.

Keep reading... Show less
Leveljump Healthcare Corp. Announces $3.2 Million Term Loan Commitment from TD Canada Trust

Leveljump Healthcare Corp. Announces $3.2 Million Term Loan Commitment from TD Canada Trust

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce that it has secured a term loan commitment from TD Canada Trust for $3.2 million for the purpose of closing the Company's previously announced acquisition of three Ontario Diagnostic Imaging Clinics (Press release September 28, 2021).

Combined with the Company's cash on hand, the term loan will allow the Company to close the Ontario Diagnostic Imaging Clinics acquisition.

Keep reading... Show less
Leveljump Healthcare Corp. Announces 13.1% Minority Investment in Real Time Medical

Leveljump Healthcare Corp. Announces 13.1% Minority Investment in Real Time Medical

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce that, subject to regulatory approval, it has agreed to acquire an outstanding 13.1% minority equity interest in Real Time Medical Inc. ("RTM"), a private Ontario company, in exchange for 2,244,576 units (a "Unit") of Leveljump. Each Unit will be issued at a price of $0.66 per Unit with each Unit being comprised of three (3) Leveljump common shares at a deemed price of $0.22 per share and one (1) share purchase warrant of Leveljump, each warrant entitling the holder to acquire one additional common share of Leveljump at a price of $0.35 per common share on or before December 31, 2023.

The equity interest in RTM was acquired through a mini-tender offer to the shareholders of RTM dated November 1, 2021 whereby JUMP offered to acquire up to 19.9% of RTM in exchange for the Units. The holders of the RTM shares who have tendered are all accredited investors.

Keep reading... Show less
HealthTab to Offer Abbott's i-STAT Alinity, Expanding Chronic Disease Testing to Select Community Pharmacies in Canada

HealthTab to Offer Abbott's i-STAT Alinity, Expanding Chronic Disease Testing to Select Community Pharmacies in Canada

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) ("Avricore Health" or the "Company") is pleased to announce the signing of a non-exclusive, pilot supplier distribution agreement in Canada between HealthTab™ Inc., a wholly owned subsidiary, and Abbott, the global healthcare company, with respect to the handheld blood chemistry analyzer, i-STAT Alinity.

The agreement allows HealthTab to distribute Abbott's point-of-care i-STAT Alinity and its associated tests for creatinine in Canadian pharmacies to better support patients with important information about their renal function.

Keep reading... Show less

Medtronic Reports Second Quarter Fiscal 2022 Financial Results

- Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2022, which ended October 29, 2021 .

Keep reading... Show less

Abbott Launches Similac® 360 Total Care® with Exclusive Blend of Five HMO Prebiotics and Designed to Support the Immune System, Digestive Health and Brain Development

Abbott (NYSE: ABT) today announced the launch of Similac 360 Total Care, the company's next generation of infant formula with HMOs, major prebiotics structurally identical to those found in human breast milk. Similac 360 Total Care is the first and only infant formula in the U.S. with a blend of five different HMOs, previously only found together in breast milk. This formula is designed to provide nutrition to support the whole baby's health and development, including the developing immune system, digestive system and brain.

Abbott scientists have been studying HMOs in breast milk for more than two decades. While breast milk is the gold standard of infant nutrition, nearly 75% of parents introduce infant formula within the first six months of a baby's life for a variety of reasons. Abbott supports parents, whatever their feeding choice. Now with the introduction of Similac 360 Total Care, parents can use a formula with a blend of five specific HMOs, previously only available to infants through breast milk.

Keep reading... Show less

Top News

Related News